Beta blockade in diabetic heart failure.
Lukas
Mary Ann
MA
Cardiovascular Medicine Development Centre, GlaxoSmithKline, Philadelphia, PA 19102, USA. mary.ann.lukas@gsk.com
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D013564:Sympathetic Nervous System / Q000187:drug effects; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists